Longer Duration of Treatment with ICIs Associated with a Higher Rate of Complete Response Among Patients with MMRd Cancers By Ogkologos - March 5, 2025 454 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a systematic review of published studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR When You Have to Make Decisions for a Loved One With... November 9, 2020 EMA Recommends Extension of Therapeutic Indications for Pembrolizumab May 6, 2022 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... August 16, 2021 For Cancer Screening, COVID-19 Pandemic Creates Obstacles, Opportunities March 10, 2021 Load more HOT NEWS Neoadjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy Can Be Delivered Safely in Patients with Operable... What People With Cancer and Survivors Should Know About Vaping: An... 確診癌症後患者應如何面對悲傷 FDA Extends Approval of Pembrolizumab for Classical Hodgkin Lymphoma
